Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).
The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.
The Immunotherapy for the Treatment of Lung Cancer module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of lung cancer. The module also includes case studies on immunotherapy for the treatment of lung cancer.
This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
Deepa Rangachari, MD
Instructor, Medicine, Harvard Medical School
Beth Israel Deaconess Medical Center
At the conclusion of this activity, the participant should be able to:
Discuss the clinical data on the efficacy and mechanism of action of approved therapies
Recognize patient selection criteria for approved therapies
Describe appropriate dosing and sequencing therapies
Identify the appropriate clinical management of common side effects of immunotherapy agents
Implement cancer immunotherapy for the treatment of lung cancers
Describe the rationale for common approaches to cancer immunotherapy in treatment of naive NSCLC patients
Explain the role of biomarkers associated with response or lack of response to immunotherapy including PD-L1, tumor mutational burden (TMB), and epidermal growth factor receptor (EGFR)
Continuing Education Information
Approximate Time to Complete: 45 minutes
Credit Available: April 25, 2019 - April 25, 2020
Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.
This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - JA4008162-9999-19-728-H01-P)
Type of Activity: Knowledge
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours. Designated for 0.4 pharmacotherapy contact hours for Advanced Practice Registered Nurses.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Deepa Rangachari, MD: No conflict of interest to report.
Planners and Managers
The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose.
Method of Participation and Request for Credit
There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please following the steps below:
- After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
- Under Pending Credit, click Request Credit for the appropriate course title.
- Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
- Complete the post-test and survey.
- Click Process Credit.
- Your Certificate will be available to view in the Submitted Credit section.
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.
Hardware and Software Requirements
SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact PIM: www.pimed.com.